A B S T R A C T Peripheral blood lymphocytes from multiple sclerosis (MS) patients form substantially greater numbers of rosettes with measles virusinfected human epithelial cells than do lymphocytes from healthy controls or from patients with other diseases. We have previously shown that prostaglandin El-treated normal lymphocytes exhibit increased lymphocyte adherence, and thus behave like MS lymphocytes in this in vitro system. In this study we describe the effect of prostaglandin synthesis inhibition on lymphocyte adherence in both MS and control patients. Direct addition of aspirin or indomethacin to peripheral blood mononuclear cells from MS patients in vitro reduced lymphocyte adherence to control levels. Ingestion of therapeutic (anti-inflammatory) doses of aspirin (1 g, 4 times daily for 2 d) by MS patients resulted in reduction of lymphocyte adherence to levels seen in healthy controls. A single 325-mg dose of aspirin did not reduce lymphocyte adherence. A dose-dependent reduction in lymphocyte adherence was observed after single doses ranging from 650 mg to 1.3 g; duration of the effect was directly related to the aspirin dose. These observations indicate that treatment of MS patients with aspirin profoundly influences adherence of their lymphocytes to measles virus-infected cells and suggest that the altered cellular response, which results in increased lymphocyte adherence in MS patients, may be mediated by a prostaglandin-sensitive mechanism.
INTRODUCTION
Lymphocytes from patients with multiple sclerosis (MS)' adhere in significantly greater numbers to
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IAbbreviations used in this paper: HEp-2, human epithelial; LAD, lymphocyte adherence determination(s); MS, multiple sclerosis. 154 measles virus-infected cells than lymphocytes from healthy controls (1, 2) . We have shown (3) (6) , infected cells were monitored weekly by hemadlsorption with rhesus monkey erythrocytes. Cultures were not used unless 90-95% of cells exhibited antigen. Cells were maintained in Eagle's minimum essential medium suppleinented with 10% fetal calf serum.
Lymphocyte adherence determination (LAD). NIOIiolayers of infected HEp-2 cells were dispersed with 0.54 mMN disodium ethylenediamine-tetra-acetate. Cells were washed three times in Hanks' balanced salt solution, pH 7.0-7.2. Lymphocytes (1.5 x 106) were incubated (37°C for 30 min) with 1.5 x 105 HEp-2 cells in a final volume of 1 ml. Cells were centrifuged (200 g for 3 min), resuspended, and examined for lymphocyte adherence. A total of 250-300 HEp-2 cells were counted, and epithelial cells to which three or more lymphocytes had adhered were counted as positive. Lymphocyte adherence is expressed as the percentage of HEp-2 cells with three or more adherent lymphocytes (percent LAD).
Serum salicylate levels. Serum salicylate levels were determined by a modification of the Natelson colorimetric technique (7) . Pooled human serum with a salicylate level of 25 mg/dl was used as a standard.
RESULTS
Effect of acetylsalicylic acid (in vitro) on lymphocyte adherence. Results of LAD are shown in Table I . In all experiments, MS lymphocytes incubated with 0.5 mM acetylsalicylic acid exhibited reduced capacity to bind to measles virus-infected HEp-2 cells. The mean+SEM percent positive HEp-2 cell adherence for acetylsalicylic acid-treated MS lymphocytes (14.1 +2.6) was significantly different (P < 0.01) from the value (55.2+2.3) for untreated cells. The effect of acetylsalicylic acid was dose-dependent (0.5 mM -0.5 nM) (data not shown). Acetylsalicylic acid had no significant effect on adherence of normal lymphocytes. Similar results were obtained when mononuclear cells were incubated with 30 puM indomethacin (Table I) .
Acetylsalicylic acid did not alter the binding of MS or control lymphocytes to uninfected HEp-2 cells.
Effect of aspirin (in vivo) on lymphocyte adherence. Adherence of MS lymphocytes to measles virus-inifected HEp-2 cells was reduced significantly after patients were treated with therapeutic (anti-inflammatory) doses of aspirin for 2 d (Table II) . The mean±+-SEM (1, 2) . The addition to normal lymphocytes of low concentrations of prostaglandin El (10 nM) increases adherence to MS levels (3, 8) . The results presented here provide evidence that ingestion of aspirin (>650 mg) by MS patients results in a significant reduction in lymphocyte adherence. Direct addition of aspirin or indomethacin to MS mononuclear cells in vitro also reduces lymphocyte adherence to normal levels in a dose-dependent fashion.
A single dose of 325 mg aspirin, which is sufficient to inhibit platelet cyclooxygenase for 2 d (9), had no effect on the LAD. These results suggest that inhibition of mononuclear cell rather than platelet cyclooxygenase contributes to the reduction in LAD. Evidence does exist (10) that the cyclooxygenase in other tissue is more resistant to aspirin than the platelet enzyme. Thus, the dose which is necessary to inhibit prostaglandin synthesis in different tissues can vary from 325 mg to 7 g/d (11) (12) (13) Prostaglandins may alter cell-surface topography such that more lymphocytes express the receptor necessary for their attachment to measles virusinfected cells. This potential capability is suggested by the observation (14) that prostaglandin El can increase theta antigen expression on the surface of lymphocytes from thymectomized mice.
It is not known whether the lymphocyte adherence determination will be useful in evaluation of patients with possible MS; initial experience with it suggests that in some circumstances its use may facilitate diagnosis (2) . It is clear from the studies presented here that the influence of inhibitors of prostaglandin synthesis must be considered when the LAD is performed. In any event, better understanding of the mechanisms responsible for the abnormal cell-cell interactions exhibited by lymphocytes from MS patients should provide useful insights into the pathogenesis of MS.
